Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor

References

• Dexter, D. L.; Hesson, D. P.; Ardecky, R. J.; Rao, G. V.; Tippett, D. L.; Dusak, B. A.; Paull, K. D.; Plowman, J.; DeLarco, B. M.; Narayanan, V. L.; Forbes, M. Activity of a Novel 4-Quinolinecarboxylic Acid, NSC 368390 [6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-yl)-3-Methyl-4-Quinolinecarb Oxylic Acid Sodium Salt], against Experimental Tumors. Cancer Res. 1985, 45, 5563–5568.
   PubMed Web of Science ®Google Scholar
• Chen, S. F.; Ruben, R. L.; Dexter, D. L. Mechanism of Action of the Novel Anticancer Agent 6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-yl)-3-Methyl-4-Quinolinecarbo Xylic Acid Sodium Salt (NSC 368390): Inhibition of de Novo Pyrimidine Nucleotide Biosynthesis. Cancer Res. 1986, 46, 5014–5019.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Sharma, S. L.; Laurensse, E.; Pinedo, H. M. Inhibition of Pyrimidine de Novo Synthesis by DUP-785 (NSC 368390). Invest New Drugs 1987, 5, 235–244.
   PubMed Web of Science ®Google Scholar
• Cadman, E. C.; Dix, D. E.; Handschumacher, R. E. Clinical, Biological, and Biochemical Effect of Pyrazofurin. Cancer Res. 1978, 38, 682–688.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Laurensse, E.; Leyva, A.; Pinedo, H. M. A Sensitive, Non-Radiometric Assay for Dihydroorotic Acid Dehydrogenase Using Anion-Exchange High-Performance Liquid Chromatography. Anal. Biochem. 1987, 161, 32–38.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Nadal, J. C.; Laurensse, E. J.; De Kant, E.; Pinedo, H. M. Retention of in Vivo Antipyrimidine Effects of Brequinar Sodium (DUP-785; NSC368390) in Murine Liver, Bone Marrow and Colon Cancer. Biochem. Pharmacol. 1990, 39, 135–144.
   PubMed Web of Science ®Google Scholar
• Schwartsmann, G.; Dodion, P.; Vermorken, J. B.; ten Bokkel Huinink, W. W.; Joggi, J.; Winograd, B.; Gall, H.; Simonetti, G.; van der Vijgh, W. J. F.; van Hennik, M. B.; et al. Phase I Study of Brequinar Sodium (NSC 368390) in Patients with Solid Malignancies. Cancer Chemother. Pharmacol. 1990, 25, 345–351.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Schwartsmann, G.; Nadal, J. C.; Laurensse, E. J.; Van Groeningen, C. J.; Van der Vijgh, W. J. F.; Pinedo, H. M. In Vivo Inhibition of the Pyrimidine de Novo Enzyme Dihydroorotic Acid Dehydrogenase by Brequinar Sodium (DUP-785; NSC 368390) in Mice and Patients. Cancer Res. 1990, 50, 4644–4649.
   PubMed Web of Science ®Google Scholar
• Bork, E.; Vest, S.; Hansen, H. H. A Phase I Clinical and Pharmacokinetic Study of Brequinar Sodium, DUP 785 (NSC 368390), Using a Weekly and a Biweekly Schedule. Eur. J. Cancer Clin. Oncol. 1989, 25, 1403–1411.
   PubMedGoogle Scholar
• Arteaga, C. L.; Brown, T. D.; Kuhn, J. G.; Shen, H. S.; O'Rourke, T. J.; Beougher, K.; Brentzel, H. J.; Von Hoff, D. D.; Weiss, G. R. Phase I Clinical and Pharmacokinetic Trial of Brequinar Sodium (DuP 785; NSC 368390). Cancer Res. 1989, 49, 4648–4653.
   PubMed Web of Science ®Google Scholar
• Dodion, P. F.; Wagener, T.; Stoter, G.; Drozd, A.; Lev, L. M.; Skovsgaard, T.; Renard, J.; Cavalli, F. Phase II Trial with Brequinar (DUP-785, NSC 368390) in Patients with Metastatic Colorectal Cancer: A Study of the Early Clinical Trials Group of the EORTC. Ann. Oncol. 1990, 1, 79–80.
   PubMed Web of Science ®Google Scholar
• Natale, R.; Wheeler, R.; Moore, M.; Dallaire, B.; Lynch, W.; Carlson, R.; Grillo-Lopez, A.; Gyves, J. Multicenter Phase II Trial of Brequinar Sodium in Patients with Advanced Melanoma. Ann. Oncol. 1992, 3, 659–660.
   PubMed Web of Science ®Google Scholar
• Urba, S.; Doroshow, J.; Cripps, C.; Robert, F.; Velez-Garcia, E.; Dallaire, B.; Adams, D.; Carlson, R.; Grillo-Lopez, A.; Gyves, J. Multicenter Phase II Trial of Brequinar Sodium in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck. Cancer Chemother. Pharmacol. 1992, 31, 167–169.
   PubMed Web of Science ®Google Scholar
• Maroun, J.; Ruckdeschel, J.; Natale, R.; Morgan, R.; Dallaire, B.; Sisk, R.; Gyves, J. Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Lung Cancer. Cancer Chemother. Pharmacol. 1993, 32, 64–66.
   PubMed Web of Science ®Google Scholar
• Moore, M.; Maroun, J.; Robert, F.; Natale, R.; Neidhart, J.; Dallaire, B.; Sisk, R.; Gyves, J. Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Gastrointestinal Cancer. Invest. New Drugs. 1993, 11, 61–65.
   PubMed Web of Science ®Google Scholar
• Cody, R.; Stewart, D.; DeForni, M.; Moore, M.; Dallaire, B.; Azarnia, N.; Gyves, J. Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Breast Cancer. Am. J. Clin. Oncol. 1993, 16, 526–528.
   PubMed Web of Science ®Google Scholar
• Lewis, T. A.; Sykes, D. B.; Law, J. M.; Muñoz, B.; Rustiguel, J. K.; Nonato, M. C.; Scadden, D. T.; Schreiber, S. L. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. ACS Med. Chem. Lett. 2016, 7, 1112–1117.
   PubMed Web of Science ®Google Scholar
• Sykes, D. B.; Kfoury, Y. S.; Mercier, F. E.; Wawer, M. J.; Law, J. M.; Haynes, M. K.; Lewis, T. A.; Schajnovitz, A.; Jain, E.; Lee, D.; et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell 2016, 167, 171–186.
   PubMed Web of Science ®Google Scholar
• Vyas, V. K.; Ghate, M. Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors. Mrmc. Chem. 2011, 11, 1039–1055.
   Web of Science ®Google Scholar
• Löffler, M. The “Anti-Pyrimidine Effect” of Hypoxia and Brequinar Sodium (NSC 368390) Is of Consequence for Tumor Cell Growth. Biochem. Pharmacol. 1992, 43, 2281–2287.
   PubMed Web of Science ®Google Scholar
• Boven, E.; Winograd, B.; Fodstad, O.; Lobbezoo, M. W.; Pinedo, H. M. Preclinical Phase II Studies in Human Tumor Lines: A European Multicenter Study. Eur. J. Cancer Clin. Oncol. 1988, 24, 567–573.
   PubMedGoogle Scholar
• Braakhuis, B. J. M.; van Dongen, G. A.; Peters, G. J.; van Walsum, M.; Snow, G. B. Antitumor Activity of Brequinar Sodium (Dup-785) against Human Head and Neck Squamous Cell Carcinoma Xenografts. Cancer Lett. 1990, 49, 133–137.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Laurensse, E.; de Kant, E.; Nadal, J. C.; Pinedo, H. M. The Relationship between Dihydroorotic Acid Dehydrogenase and in Vitro and in Vivo Cytostatic Effects of Brequinar Sodium (DUP-785; NSC 368390). Adv. Exp. Med. Biol. 1989, 253B, 375–382.
   PubMedGoogle Scholar
• Hey-Mogensen, M.; Goncalves, R. L.; Orr, A. L.; Brand, M. D. Production of Superoxide/H2O2 by Dihydroorotate Dehydrogenase in Rat Skeletal Muscle Mitochondria. Free Radic. Biol. Med. 2014, 72, 149–155.
   PubMed Web of Science ®Google Scholar
• Finkelstein, E.; Rosen, G. M.; Rauckman, E. J. Spin Trapping of Superoxide and Hydroxyl Radical: Practical Aspects. Arch. Biochem. Biophys. 1980, 200, 1–16.
   PubMed Web of Science ®Google Scholar
• Mans, D. R.; Retèl, J.; van Maanen, J. M.; Lafleur, M. V.; van Schaik, M. A.; Pinedo, H. M.; Lankelma, J. Role of the Semi-Quinone Free Radical of the anti-Tumour Agent Etoposide (VP-16-213) in the Inactivation of Single- and Double-Stranded Phi X174 DNA. Br. J. Cancer. 1990, 62, 54–60.
   PubMed Web of Science ®Google Scholar
• El Kouni, M. H.; Naguib, F. N. M.; Kyung Sun, P.; Sungman, C.; Darnowskl, J. W.; Soong, S.-J. Circadian Rhythm of Hepatic Uridine Phosphorylase Activity and Plasma Concentration of Uridine in Mice. Biochem. Pharmacol. 1990, 40, 2479–2485.
   PubMed Web of Science ®Google Scholar
• de Kant, E.; Pinedo, H. M.; Laurensse, E.; Peters, G. J. The Relation between Inhibition of Cell Growth and of Dihydroorotic Acid Dehydrogenase by Brequinar Sodium. Cancer Lett. 1989, 46, 123–127.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg, A. B. P.; Poorter, R. L.; Peters, G. J.; Van Gennip, A. H.; Van Lenthe, H.; Stroomer, A. E. M.; Smid, K.; Noordhuis, P.; Bakker, P. J. M.; Veenhof, C. H. N. No, Circadian Variation of Dihydropyrimidine Dehydrogenase, Uridine Phosphorylase, ß-Alanine and 5-Fluorouracil during Continuous Infusion of 5-Fluoruoracil. Adv. Exp. Med. Biol. 1998; 431, 815-816. Eur. J. Cancer 1995, 31, S198.
   Google Scholar
• Shen, H. S.; Chen, S. F.; Behrens, D. L.; Whitney, C. C.; Dexter, D. L.; Forbes, M. Distribution of the Novel Anticancer Drug Candidate Brequinar Sodium (DuP 785, NSC 368390) into Normal and Tumor Tissues of Nude Mice Bearing Human Colon Carcinoma Xenografts. Cancer Chemother. Pharmacol. 1988, 22, 183–186.
   PubMed Web of Science ®Google Scholar
• Schwartsmann, G.; van der Vijgh, W. J. F.; van Hennik, M. B.; Klein, I.; Vermorken, J. B.; Dodion, P.; ten Bokkel Huinink, W. W.; Joggi, G.; Gall, H.; Crespeigne, N.; et al. Pharmacokinetics of Brequinar Sodium (NSC 368390) in Patients with Solid Tumors during a Phase I Study. Eur. J. Cancer Clin. Oncol. 1989, 25, 1675–1681.
   PubMedGoogle Scholar
• Darnowski, J. W.; Handschumacher, R. E. Tissue Uridine Pools: Evidence in Vivo of a Concentrative Mechanism for Uridine Uptake. Cancer Res. 1986, 46, 3490–3494.
   PubMed Web of Science ®Google Scholar
• Buzaid, A. C.; Pizzorno, G.; Marsh, J. C.; Ravikumar, T. S.; Murren, J. R.; Todd, M.; Strair, R. K.; Poo, W. J.; Hait, W. N. Biochemical Modulation of 5-Fluorouracil with Brequinar: Results of a Phase I Study. Cancer Chemother. Pharmacol. 1995, 36, 373–378.
   PubMed Web of Science ®Google Scholar
• Schultz, M.; Keeling, S. O.; Katz, S. J.; Maksymowych, W. P.; Eurich, D. T.; Hall, J. J. Clinical Effectiveness and Safety of Leflunomide in Inflammatory Arthritis: A Report from the RAPPORT Database with Supporting Patient Survey. Clin. Rheumatol. 2017, 36, 1471–1478.
   PubMed Web of Science ®Google Scholar
• Breedveld, F. C.; Dayer, J. M. Leflunomide: Mode of Action in the Treatment of Rheumatoid Arthritis. Ann. Rheum. Dis. 2000, 59, 841–849.
   PubMed Web of Science ®Google Scholar
• Xu, X.; Williams, J. W.; Shen, J.; Gong, H.; Yin, D. P.; Blinder, L.; Elder, R. T.; Sankary, Finnega, H.; Chong, A. S. In Vitro and In Vivo Mechanisms of Action of the Antiproliferative and Immunosuppressive Agent, Brequinar Sodium. J. Immunol. 1998, 160, 846–853.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick, L. R.; Deml, L.; Hofmann, C.; Small, J. S.; Groeppel, M.; Hamm, S.; Lemstra, S.; Leban, J.; Ammendola, A. 4SC-101, A Novel Immunosuppressive Drug, Inhibits IL-17 and Attenuates Colitis in Two Murine Models of Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2010, 16, 1763–1777.
   PubMed Web of Science ®Google Scholar
• Boa, A. N.; Canavan, S. P.; Hirst, P. R.; Ramsey, C.; Stead, A. M.; McConkey, G. A. Synthesis of Brequinar Analogue Inhibitors of Malaria Parasite Dihydroorotate Dehydrogenase. Bioorg Med Chem 2005, 13, 1945–1967.
   PubMed Web of Science ®Google Scholar
• Adcock, R. S.; Chu, Y. K.; Golden, J. E.; Chung, D. H. Evaluation of anti-Zika Virus Activities of Broad-Spectrum Antivirals and NIH Clinical Collection Compounds Using a Cell-Based, High-Throughput Screen Assay. Antiviral Res. 2017, 138, 47–56.
   PubMed Web of Science ®Google Scholar
• Seymour, K. K.; Lyons, S. D.; Phillips, L.; Rieckmann, K. H.; Christopherson, R. I. Cytotoxic Effects of Inhibitors of de Novo Pyrimidine Biosynthesis upon Plasmodium falciparum. Biochemistry 1994, 3;33, 5268–5274.
   Google Scholar
• Peters, G. J.; Kraal, I.; Pinedo, H. M. In Vitro and in Vivo Studies on the Combination of Brequinar Sodium (DUP-785; NSC 368390) with 5-Fluorouracil; Effects of Uridine. Br. J. Cancer. 1992, 65, 229–233.
   PubMed Web of Science ®Google Scholar